**Disclosure**: The authors declare that they have no conflict of interest.

Introduction {#os12465-sec-0006}
============

Recent treatment regimens have prolonged median survival time in patients with cancer, which has consequently led to a high frequency of metastatic spinal cord compression (MSCC) during the remaining lifetime of these patients. Approximately, 70% of patients with cancer develop spinal metastases[1](#os12465-bib-0001){ref-type="ref"}, [2](#os12465-bib-0002){ref-type="ref"}, 20% of whom develop neurological deficits[3](#os12465-bib-0003){ref-type="ref"}, [4](#os12465-bib-0004){ref-type="ref"}, [5](#os12465-bib-0005){ref-type="ref"}. Almost 10% of patients with MSCC choose to undergo surgical decompression with or without stabilization[4](#os12465-bib-0004){ref-type="ref"}, [6](#os12465-bib-0006){ref-type="ref"}, [7](#os12465-bib-0007){ref-type="ref"}, [8](#os12465-bib-0008){ref-type="ref"}, which can restore neurological function and improve their quality of life. However, it is not yet clear how to identify the patients who would benefit most from surgical treatment. It is generally accepted that life expectancy drives treatment regimens for spine metastases[9](#os12465-bib-0009){ref-type="ref"}. For example, decompressive surgery is generally not considered indicated in patients with life expectancies of less than 3 months[10](#os12465-bib-0010){ref-type="ref"}.

Some surgeons and radiologists have therefore established various prognostic scoring systems for predicting survival to help decide in selection of the most appropriate treatment strategy[11](#os12465-bib-0011){ref-type="ref"}. Unsurprisingly, because visceral metastases are considered to indicate the terminal stage in patients with cancer and their treatment is palliative rather than curative, visceral metastases have been regarded as one of the most important, and therefore commonly used, prognostic factors. This factor has therefore been incorporated into all of these scoring systems[12](#os12465-bib-0012){ref-type="ref"}, [13](#os12465-bib-0013){ref-type="ref"}, [14](#os12465-bib-0014){ref-type="ref"}, [15](#os12465-bib-0015){ref-type="ref"}, [16](#os12465-bib-0016){ref-type="ref"}, [17](#os12465-bib-0017){ref-type="ref"}, [18](#os12465-bib-0018){ref-type="ref"}, [19](#os12465-bib-0019){ref-type="ref"}.

However, recently published studies have reported significantly disparate findings concerning the effect of visceral metastases on survival. Arrigo *et al.* [20](#os12465-bib-0020){ref-type="ref"} reported that visceral metastases do not significantly influence survival after surgery in patients with MSCC. Chong *et al.* [21](#os12465-bib-0021){ref-type="ref"} investigated preoperative prognostic factors in 108 patients and showed that visceral metastases are not an independent prognostic factor despite the median survival of patients with visceral metastases at the time of surgery being 4.0 months and that of patients without visceral metastases 11.0 months. Therefore, there is controversy over whether visceral metastases are a prognostic factor in patients with spinal metastases.

The current study was performed with the goals of further identifying the role of visceral metastases in predicting survival time in patients with spinal metastases and determining the difference in prognosis between patients with and without visceral metastases.

Methods {#os12465-sec-0007}
=======

This study was approved by the hospital Ethics Committee. Three institutional databases were searched to identify all patients with spinal metastases and Tokuhashi score 9--15 between March 2002 and June 2010[14](#os12465-bib-0014){ref-type="ref"}.

The inclusion criteria for performing surgical interventions comprised intractable pain despite medication, rapidly progressive neurological deterioration, and evidence of clinical or radiographic instability.

The exclusion criteria comprised spinal metastases without cord compression, treatment by radiotherapy or revision procedures, operative procedure vertebroplasty or kyphoplasty only, life expectancy less than 3 months, and patients whose medical condition was considered too poor to tolerate surgery. Life expectancy was estimated on the basis of the revised Tokuhashi scoring system. Additionally, surgery was selected by mutual agreement between the surgeon and patient.

Survival data were obtained from medical records, by telephone follow‐up, or searching a governmental cancer registry. The patients were divided into two groups according to whether they had visceral metastases. Patient characteristics, including preoperative and postoperative medical conditions, were collected from medical records or by telephone follow‐up. Selected possible prognostic factors were analyzed, and each variable was categorized into two or three groups as follows: age (\<65 vs. ≥65 years), sex (female vs. male), rate of growth of primary tumor (rapid vs. moderate vs. slow), preoperative and postoperative Frankel scores (A--C vs. D--E), other bone metastases (no vs. yes), preoperative and postoperative Karnofsky performance status (KPS) (10--40 vs. 50--70 vs. 80--100), number of involved vertebrae (solitary vs. multiple), pathological fracture (no vs. yes), metastasis site (cervical vs. non‐cervical), serum albumin concentration(\<35 g/L vs. ≥35 g/L), sphincter dysfunction (no vs. yes), and interval between developing motor deficits and surgery (≤5 vs. \>5 days).

On the basis of findings reported by Tomita[12](#os12465-bib-0012){ref-type="ref"}, primary cancer types were categorized according to growth rate as follows: slow growth (breast, prostate, thyroid, etc.), moderate growth (kidney, uterus, etc.) and rapid growth (lung, colon, liver, gastric cancer, and other cancers).

Postoperative survival was defined as the time between the date of surgery and death or the latest follow‐up. Neurological function was graded according to Frankel grade preoperatively and 4 weeks postoperatively (patients with Frankel D and E are able to walk). Time to developing motor deficits was defined as interval between deterioration of motor function and surgery. Deterioration of motor function was defined as a change of at least one Frankel grade.

*Statistical Analysis* {#os12465-sec-0008}
----------------------

Mean values are reported as mean ± standard deviation and median values with range. The characteristics of the two groups were compared using the χ^2^ or Student\'s *t‐*test, and a two‐tailed *P* \<0.05 was considered to denote statistical significance. Univariate analysis of survival was performed using the Kaplan--Meier method and log‐rank test. Variables significant at *P* \< 0.01 in the univariate analysis were tested through a backward stepwise selection process for their independent effect on overall survival (OS). Rate ratios and their 95% confidence intervals (CIs) were computed, as were odds ratios and their 95% CIs. *P* \< 0.05 was considered to denote statistical significance.

Results {#os12465-sec-0009}
=======

*Patient Characteristics* {#os12465-sec-0010}
-------------------------

Patient characteristic according to group are summarized in Table [1](#os12465-tbl-0001){ref-type="table"}. There were 102 men and 67 women with a mean age of 59.6 ± 10.5 years (range, 18--84 years). Forty‐two patients had visceral metastases at the time of spinal surgery and 127 did not. The primary cancers were lung cancer (73 patients, 43%), breast cancer (13, 8%), renal cancer (12, 7%), hepatic cancer (10, 6%), gastrointestinal cancer (nine, 5%), prostate cancer (seven, 4%), and other (45, 27%).

###### 

Baseline characteristics of the study cohort and patient subgroups

  Variables                                                         All patients                       Patients with visceral metastasis   Patients without visceral metastasis   *P* value
  --------------------------------------------- ----------------------------------------------------- ----------------------------------- -------------------------------------- -----------
  Number of patients                                                     169                                          42                                   127                       ---
  Age(mean ± SD)                                                     59.6 ± 10.5                                  60.3 ± 11.4                          59.4 ± 10.3                  0.733
  Age‐N (%)                                                             0.477                                                                                                    
  \<65                                                                   109                                          29                                    80                   
  ≥65                                                                    60                                           13                                    47                   
  Gender‐N (%)                                                          0.423                                                                                                    
  Male                                                                   102                                          23                                    79                   
  Female                                                                 67                                           19                                    48                   
  Systematic co‐morbidity‐N (%)                                         0.729                                                                                                    
  Yes                                                                    56                                           13                                    43                   
  No                                                                     113                                          29                                    84                   
  Type of primary tumor‐N (%)                                           0.136                                                                                                    
  Group A (rapid)                                                        78                                           14                                    64                   
  Group B (moderate)                                                     65                                           19                                    46                   
  Group C (slow)                                                         26                                            9                                    17                   
  Location of involved vertebrae‐N (%)                                  0.778                                                                                                    
  Cervical                                                               22                                            6                                    16                   
  Non‐cervical                                                           147                                          36                                   111                   
  Frankel grade pre‐operation‐N (%)                                     0.437                                                                                                    
  A‐C                                                                    37                                           11                                    26                   
  D‐E                                                                    132                                          31                                   101                   
  Extrospinal bone metastasis‐N (%)                                     0.229                                                                                                    
  Yes                                                                    113                                          22                                    53                   
  No                                                                     56                                           20                                    74                   
  Pathological fracture‐N (%)                                           0.720                                                                                                    
  Yes                                                                    33                                            9                                    24                   
  No                                                                     136                                          33                                   103                   
  Number of involved vertebrae‐N(%)                                     0.826                                                                                                    
  Yes                                                                    41                                           20                                    58                   
  No                                                                     128                                          22                                    69                   
  Preoperative KPS‐N (%)                          **0.044** [\*](#os12465-note-0001){ref-type="fn"}                                                                              
  10--40                                                                 19                                            8                                    11                   
  50--70                                                                 94                                           17                                    77                   
  80--100                                                                56                                           17                                    39                   
  Time to developing motor deficit‐N (%)                                0.446                                                                                                    
  ≤5 days                                                                121                                          32                                    89                   
  \>5 days                                                               48                                           10                                    38                   
  Urinary retention/incontinence‐N (%)                                  0.877                                                                                                    
  Yes                                                                    13                                            3                                    10                   
  No                                                                     156                                          39                                   117                   
  Serum album level (g/l)‐N (%)                  **\<0.001** [\*](#os12465-note-0001){ref-type="fn"}                                                                             
  \<35g/l                                                                17                                           10                                    7                    
  ≥35g/l                                                                 96                                           18                                    78                   
  Adjuvant therapy‐N (%)                                                0.304                                                                                                    
  Yes                                                                    125                                          24                                   101                   
  No                                                                     44                                            4                                    40                   
  Local relapse after treatment‐N (%)                                   0.375                                                                                                    
  Yes                                                                    32                                            6                                    26                   
  No                                                                     137                                          36                                   101                   
  Major complications post‐operation‐N (%)                              0.649                                                                                                    
  Yes                                                                    15                                            3                                    12                   
  No                                                                     154                                          39                                   115                   
  Change on Frankel grade‐N (%)                                         0.414                                                                                                    
  Deteriorated                                                           15                                            2                                    13                   
  Not changed                                                            75                                           24                                    51                   
  Improved                                                               79                                           16                                    63                   
  Change on Karnofsky performance score‐N (%)                           0.306                                                                                                    
  Deteriorated                                                           22                                            6                                    16                   
  Not changed                                                            46                                           14                                    32                   
  Improved                                                               101                                          22                                    79                   

Note: \*, statistical significance; N, number.

The median and mean postoperative survival times were 7.0 ± 0.5 (95%CI 6.0--8.0) months and 12.6 ± 1.2 (95%CI 10.1--15.0) months, respectively, in the whole cohort, being 5.0 ± 0.5 (95%CI 4.0--6.0) months and 10.8 ± 2.4 (95%CI 6.1--15.5) months, respectively, in patients with visceral metastases and 7.0 ± 0.8 (95% CI 5.4--8.6) months and 13.0 ± 1.4 (95% CI 10.3--15.6) months, respectively, in patients without visceral metastases (*P* = 0.87) (Fig. [1](#os12465-fig-0001){ref-type="fig"}). There was a trend toward lower OS rates in patients with visceral metastases compared with those without them; however, this difference was not significant (HR 1.28, 95% CI 0.82--2.01, *P* = 0.277). The 6‐ and 12‐month OS rates for the entire cohort were 51.6% and 32.7%, respectively, being 39.0% and 23.3% for patients with visceral metastases and 55.7% and 35.8%, respectively, for patients without visceral metastases. Figure shows the Kaplan--Meier survival of the whole group, and the subgroups with and without visceral metastases.

![Kaplan--Meier survival analysis for whole cohort and subgroups with and without visceral metastases.](OS-11-414-g001){#os12465-fig-0001}

Compared with patients without visceral metastases, those with visceral metastases had significantly poorer performance status (eight \[19.0%\] vs. 11 \[8.6%\] had KPS \<50, *P* \< 0.044) and lower preoperative serum albumin concentrations (10 \[35.7%\] vs. seven \[8.2%\] had \<35 g/L, *P* \< 0.001). There was no statistically significant difference in any of the following characteristics between the two groups: age (*P* = 0.733), sex (*P* = 0.423), preoperative and postoperative Frankel scores (*P* = 0.437 and 0.507), other bone metastases (*P* = 0.292), postoperative KPS (*P* = 0.384), number of involved vertebrae (*P* = 0.826), pathological fracture (*P* = 0.720), metastasis site (*P* = 0.788), sphincter dysfunction (*P* = 0.877), interval between developing motor deficits and surgery (*P* = 0.466), change in Frankel grade (*P* = 0.414), and KPS (*P* = 0.306) (Table [1](#os12465-tbl-0001){ref-type="table"}).

*Overall Prognostic Factors* {#os12465-sec-0011}
----------------------------

Univariate analysis by the Kaplan--Meier method and log‐rank test identified the following significant prognostic factors for OS: rate of growth of primary tumor (*P* = 0.015), preoperative Frankel grade (*P* \< 0.001) and KPS (*P* \< 0.001), change in Frankel grade (*P* \< 0.001) and KPS (*P* \< 0.001), adjuvant therapy (*P* = 0.001), location of metastases (*P* = 0.021), and local relapse (*P* = 0.020) (Table [2](#os12465-tbl-0002){ref-type="table"}). However, multivariable analysis with maximal model identified rate of growth of primary tumor (*P* = 0.003), preoperative KPS (*P* \< 0.001), change in KPS (*P* \< 0.001), and Frankel grade (*P* = 0.091) as independent prognostic factors (Table [3](#os12465-tbl-0003){ref-type="table"}).

###### 

Results of univariate analysis by log‐rank test

  Variables                                Whole cohort (%)   Median (m)   *P* value           Patients with visceral metastasis (%)          Median (m)   *P* value   Patients without visceral metastasis (%)                       Median (m)                        *P* value                       
  --------------------------------------- ------------------ ------------ ------------ ----------------------------------------------------- ------------ ----------- ------------------------------------------ ----------------------------------------------------- ------------ ------ ------------ -----------------------------------------------------
  Type of primary tumor by growth speed                                                                                                                                                                                                                                                                 
  Group A (Rapid)                                41.1            26.5      6.0 ± 0.5     **0.015** [\*](#os12465-note-0002){ref-type="fn"}       21.4        21.4                     3.0 ± 0.9                                          0.074                             45.6      27.7   6.0 ± 0.7     **0.041** [\*](#os12465-note-0002){ref-type="fn"}
  Group B (Moderate)                             54.9            32.6      7.0 ± 1.0                           47.4                              16.8      5.0 ± 1.5                     58.1                                            38.6                           8.0 ± 1.6                       
  Group C (slow)                                 73.1            50.0      10.0 ± 3.5                          55.6                              44.4      5.0 ± 1.9                     82.4                                            52.9                           13.0 ± 4.8                      
  Gender                                                                                                                                                                                                                                                                                                
  Male                                           59.8            36.3      6.0 ± 0.7                           0.547                             46.2        38.5                     4.0 ± 0.6                                          0.250                             50.9      31.7   7.0 ± 0.6                           0.864
  Female                                         46.2            30.3      8.0 ± 1.1                           37.9                              19.7      5.0 ± 1.1                     62.7                                            41.2                           9.0 ± 1.6                       
  Age                                                                                                                                                                                                                                                                                                   
  ≥65                                            48.6            32.6      6.0 ± 1.1                           0.931                             30.4        26.1                     5.0 ± 2.2                                          0.273                             49.3      31.4   6.0 ± 1.0                           0.370
  \<65                                           53.2            32.6      7.0 ± 0.6                           52.6                              25.3      5.0 ± 0.5                     58.9                                            37.5                           8.0 ± 1.0                       
  Systematic comorbidity                                                                                                                                                                                                                                                                                
  Yes                                            46.4            32.9      6.0 ± 0.9                           0.721                             46.2        23.1                     5.0 ± 1.8                                          0.630                             46.5      36.4   6.0 ± 0.8                           0.995
  No                                             54.3            32.6      7.0 ± 0.7                           35.7                              24.5      5.0 ± 0.6                     60.6                                            35.5                           8.0 ± 0.9                       
  Visceral metastasis                                                                                                                                                                                                                                                                                   
  Yes                                            39.0            23.3      5.0 ± 0.5                           0.080                              ‐            ‐                          ‐                                                ‐                                ‐         ‐         ‐                                 ‐
  No                                             55.7            35.8      7.0 ± 0.8                             ‐                                ‐            ‐                          ‐                                                ‐                                ‐                           
  Preoperative Frankel grade                                                                                                                                                                                                                                                                            
  A‐C                                            42.4            13.8      5.0 ± 1.3    **\<0.001** [\*](#os12465-note-0002){ref-type="fn"}      27.3         9.1                     4.0 ± 0.8                    **0.035** [\*](#os12465-note-0002){ref-type="fn"}       49.0      17.8   6.0 ± 1.7     **0.006** [\*](#os12465-note-0002){ref-type="fn"}
  D‐E                                            54.2            37.6      7.0 ± 0.8                           45.2                              31.5      5.0 ± 0.9                     57.0                                            39.6                           7.0 ± 1.4                       
  Preoperative KPS                                                                                                                                                                                                                                                                                      
  80--100                                        58.3            43.3      8.0 ± 2.1    **\<0.001** [\*](#os12465-note-0002){ref-type="fn"}      41.2        29.4                     5.0 ± 0.8                                          0.240                             65.0      48.2   12.0 ± 3.5   **\<0.001** [\*](#os12465-note-0002){ref-type="fn"}
  50--70                                         53.9            32.0      7.0 ± 0.7                           47.1                              26.5      4.0 ± 1.3                     55.9                                            33.9                           7.0 ± 0.9                       
  10--40                                         21.1            0.0       3.0 ± 0.4                           25.0                              12.5      4.0 ± 0.7                     18.2                                             0.0                           3.0 ± 0.4                       
  Extrospinal bone metastasis                                                                                                                                                                                                                                                                           
  Yes                                            49.0            34.2      6.0 ± 0.8                           0.234                             36.4        27.3                     5.0 ± 0.9                                          0.466                             54.3      37.4   7.0 ± 1.2                           0.437
  No                                             53.7            31.5      7.0 ± 0.7                           45.0                              24.0      5.0 ± 0.7                     56.2                                            33.6                           7.0 ± 1.1                       
  Pathological fracture                                                                                                                                                                                                                                                                                 
  Yes                                            61.4            39.9      9.0 ± 2.1                           0.297                             44.4         0.0                     4.0 ± 0.5                                          0.868                             68.2      48.7   10.0 ± 3.7                          0.224
  No                                             49.3            31.0      6.0 ± 0.5                           39.4                              27.3      5.0 ± 0.7                     52.5                                            32.2                           7.0 ± 0.5                       
  Number of involved vertebrae                                                                                                                                                                                                                                                                          
  Solitary                                       54.8            34.8      6.0 ± 0.6                           0.075                             40.0        24.0                     5.0 ± 0.5                                          0.791                             52.6      30.3   7.0 ± 0.7                           0.253
  Multiple                                       56.8            38.5      7.0 ± 1.0                           40.9                              26.5      5.0 ± 0.9                     57.8                                            39.5                           8.0 ± 1.7                       
  Time to developing motor deficit                                                                                                                                                                                                                                                                      
  ≤5 days                                        48.2            33.1      6.0 ± 0.5                           0.370                             37.5        30.1                     5.0 ± 1.6                                          0.549                             52.0      34.1   7.0 ± 0.5                           0.159
  \>5 days                                       60.8            31.4      8.0 ± 1.0                           50.0                              10.0      5.0 ± 0.6                     64.0                                            38.1                           9.0 ± 1.6                       
  Urinary retention/incontinence                                                                                                                                                                                                                                                                        
  Yes                                            38.5            15.4      4.0 ± 0.9                           0.131                             33.3         0.0                        2.0                                             0.078                             40.0      20.0   4.0 ± 1.6                           0.322
  No                                             52.7            34.2      7.0 ± 0.6                           41.0                              27.2      5.0 ± 0.5                     56.7                                            36.6                           7.0 ± 0.8                       
  Serum album level pre‐operation                                                                                                                                                                                                                                                                       
  ≥35g/L                                         55.2            33.5      7.0 ± 0.9                           0.300                             43.8        27.1                     4.0 ± 0.8                                          0.289                             55.2      35.9   7.0 ± 1.1                           0.791
  \<35g/L                                        44.4            27.8      4.0 ± 1.0                           30.0                              20.0      4.0 ± 0.8                     57.1                                            28.6                           7.0 ± 1.8                       
  Adjuvant therapy                                                                                                                                                                                                                                                                                      
  Yes                                            59.3            33.7      8.0 ± 0.8     **0.001** [\*](#os12465-note-0002){ref-type="fn"}       50.0        32.8                     6.0 ± 1.4                                          0.090                             63.3      41.2   9.0 ± 1.3    **\<0.001** [\*](#os12465-note-0002){ref-type="fn"}
  No                                             29.0            17.8      5.0 ± 0.6                           27.8                              16.7      4.0 ± 0.8                     24.4                                            11.2                           5.0 ± 0.6                       
  Location of involved vertebrae                                                                                                                                                                                                                                                                        
  Cervical                                       66.8            50.9      14.0 ± 7.0    **0.021** [\*](#os12465-note-0002){ref-type="fn"}       33.3        33.3                        3.0                                             0.295                             80.4      57.5   18.0 ± 6.5    **0.043** [\*](#os12465-note-0002){ref-type="fn"}
  Non‐cervical                                   49.3            39.1      6.0 ± 0.6                           41.7                              23.6      5.0 ± 0.6                     51.9                                            32.3                           7.0 ± 0.7                       
  Change on Frankel grade                                                                                                                                                                                                                                                                               
  Deteriorated                                   13.3            6.7       3.0 ± 0.7    **\<0.001** [\*](#os12465-note-0002){ref-type="fn"}      0.0          0.0                        2.0                       **0.013** [\*](#os12465-note-0002){ref-type="fn"}       15.4      7.7    5.0 ± 0.7    **\<0.001** [\*](#os12465-note-0002){ref-type="fn"}
  Not changed                                    36.0            26.1      5.0 ± 0.4                           25.0                              20.8      5.0 ± 0.5                     41.2                                            28.8                           6.0 ± 0.8                       
  Improved                                       74.4            44.3      10.0 ± 2.0                          66.7                              30.0      8.0 ± 2.4                     76.6                                            47.6                           10.0 ± 1.8                      
  Change on KPS                                                                                                                                                                                                                                                                                         
  Deteriorated                                   18.2            4.5       4.0 ± 0.7    **\<0.001** [\*](#os12465-note-0002){ref-type="fn"}      20.0         0.0                     3.0 ± 1.1                   **\<0.001** [\*](#os12465-note-0002){ref-type="fn"}      17.6      5.9    5.0 ± 1.0    **\<0.001** [\*](#os12465-note-0002){ref-type="fn"}
  Not change                                     26.7            10.2      5.0 ± 0.4                            0.0                              0.0       4.0 ± 0.4                     38.8                                            14.8                           6.0 ± 0.9                       
  Improved                                       70.5            49.4      12.0 ± 1.7                          68.2                              43.4      9.0 ± 3.4                     71.1                                            51.1                           13.0 ± 1.8                      
  Local relapse                                                                                                                                                                                                                                                                                         
  Yes                                            70.0            52.1      14.0 ± 3.1    **0.020** [\*](#os12465-note-0002){ref-type="fn"}       66.7        66.7                     14.0 ± 9.0                   **0.020** [\*](#os12465-note-0002){ref-type="fn"}       70.8      48.7   10.0 ± 3.9                          0.261
  No                                             47.5            28.3      6.0 ± 0.5                           34.3                              15.7      5.0 ± 0.5                     52.1                                            32.6                           7.0 ± 0.5                       
  Major complications                                                                                                                                                                                                                                                                                   
  Yes                                            40.0            26.7      4.0 ± 1.5                           0.823                             0.0          0.0                     2.0 ± 0.0                   **\<0.001** [\*](#os12465-note-0002){ref-type="fn"}      50.0      33.3   6.0 ± 2.6                           0.492
  No                                             52.7            33.2      7.0 ± 0.6                           42.1                              25.1      5.0 ± 0.5                     56.3                                            36.0                           7.0 ± 0.8                       

Note: \*, statistical significance; KPS, Karnofsky performance status; m, months; −, not included.

###### 

Significant prognostic factors according to multivariate analysis by Cox hazard proportional model

  Prognostic factors                          Hazard ratio   95% confidence interval   *P* value
  ------------------------------------------ -------------- ------------------------- -----------
  **Whole cohort**                                                                    
  **Primary tumor**                                                                   
  Group C(slow)                                    1                    ‐                0.003
  Group B (moderate)                              1.76             1.05--2.95            0.032
  Group A (rapid)                                 2.43             1.45--4.09            0.001
  **Preoperative KPS**                                                                
  80--100                                          1                    ‐               \<0.001
  50--70                                          1.66             1.08--2.53            0.020
  10--40                                          3.72             2.05--6.76           \<0.001
  **Change on KPS**                                                                   
  Improved                                         1                    ‐               \<0.001
  Not change                                      2.62             1.69--4.04           \<0.001
  Deteriorated                                    4.26             1.98--9.17           \<0.001
  **Change on Frankel grade**                                                         
  Improved                                         1                    ‐                0.091
  Not changed                                     1.58             1.02--2.45            0.043
  Deteriorated                                    1.84             0.76--4.46            0.179
  **Patients with visceral metastasis**                                               
  **Change on KPS**                                                                   
  Improved                                         1                    ‐                0.001
  Not change                                      2.39             1.45--3.92            0.037
  Deteriorated                                    3.12             1.07--9.09            0.001
  **Major complications**                                                             
  No                                               1                    ‐                0.003
  Yes                                            11.59             2.27--59.17        
  **Patients without visceral metastasis**                                            
  **Primary tumor**                                                                   
  Group C (Slow)                                   1                    ‐                0.016
  Group B (Moderate)                              1.67             0.88--3.17            0.116
  Group A (Rapid)                                 2.37             1.29--4.37            0.005
  **Change on KPS**                                                                   
  Improved                                         1                    ‐                0.001
  Not change                                      2.45             1.36--3.71            0.002
  Deteriorated                                    3.69             1.26--10.80           0.017
  **Preoperative KPS**                                                                
  80--100                                          1                    ‐               \<0.001
  50--70                                          1.93             1.17--3.19            0.010
  10--40                                          6.72             3.12--14.50          \<0.001

Note: *P* \< 0.05 was considered to denote a significant difference; KPS, Karnofsky performance status.

*Prognostic Factors in Patients with Visceral Metastases* {#os12465-sec-0012}
---------------------------------------------------------

Preoperative Frankel score (*P* = 0.035), change in Frankel grade (*P* = 0.013) and KPS (*P* \< 0.001), local relapse (*P* = 0.020), and major complications (*P* \< 0.001) were potential prognostic factors according to univariate log‐rank test (Table [2](#os12465-tbl-0002){ref-type="table"}). The multivariate Cox regression model identified change in KPS (*P* = 0.001) and major complications (*P* = 0.003) as the only variables that were independent predictors of OS (Table [3](#os12465-tbl-0003){ref-type="table"}).

*Prognostic Factors in Patients without Visceral Metastases* {#os12465-sec-0013}
------------------------------------------------------------

Univariate analysis identified the potential prognostic factors of rate of growth of primary tumor (*P* = 0.041), preoperative Frankel score (*P* = 0.006) and KPS (*P* \< 0.001), adjuvant therapy (*P* \< 0.001), change in Frankel grade (*P* \< 0.001) and KPS (*P* \< 0.001), and location of metastases (*P* = 0.043) (Table [2](#os12465-tbl-0002){ref-type="table"}). The multivariate Cox regression model showed that primary tumor (*P* = 0.016), change in KPS (*P* = 0.001), and preoperative KPS (*P* \< 0.001) had significant influence on OS (Table [3](#os12465-tbl-0003){ref-type="table"}).

Discussion {#os12465-sec-0014}
==========

Currently, most published studies that have focused on assessing prognostic factors in patients with MSCC have failed to distinguish between patients with and without visceral metastases. To the best of our knowledge, this is the first study to investigate the impact of visceral metastases on OS and identify different prognostic factors according to visceral metastases status.

A randomized controlled study[10](#os12465-bib-0010){ref-type="ref"} and a meta‐analysis[22](#os12465-bib-0022){ref-type="ref"} have found that surgery is superior to radiotherapy alone in terms of functional outcome, pain control, and OS. However, not all patients with MSCC benefit from undergoing a surgical procedure. Especially in patients with short survival times, post‐operative complications may offset the intended benefits of surgery, or death may occur before wound healing or functional recovery.

In general, patients with very short survival times are not suitable candidates for decompressive surgery[10](#os12465-bib-0010){ref-type="ref"}. Therefore, means of accurately predicting survival time in patients with MSCC is currently an important topic to research. Various prognostic scoring systems for predicting life expectancy of patients with MSCC have been developed. The scoring systems reported by Tomita[12](#os12465-bib-0012){ref-type="ref"} and Tokuhashi[13](#os12465-bib-0013){ref-type="ref"}, [14](#os12465-bib-0014){ref-type="ref"} are the most representative and commonly used systems; both use visceral metastases as an important prognostic factor for survival in these patients.

*Effect of Visceral Metastases on Prognosis* {#os12465-sec-0015}
--------------------------------------------

Understandably, development of visceral metastases, an indicator of more aggressive tumors, is usually regarded as denoting an advanced stage of cancer. Patients with visceral metastases tend to have shorter survival because of cancer progression[3](#os12465-bib-0003){ref-type="ref"}. Lei *et al.* [23](#os12465-bib-0023){ref-type="ref"} reported that visceral metastases have a significant impact on survival in patients with MSCC from lung cancer. Crnalic *et al.* [24](#os12465-bib-0024){ref-type="ref"} observed that visceral metastases have a detrimental effect on survival of patients with prostate cancer, the median survival of patients with visceral metastases being only 4 months, as compared twitho 10 months for patients without visceral metastases. Drzymalski *et al.* [25](#os12465-bib-0025){ref-type="ref"} found that the presence of additional metastases at the time of diagnosis of spinal metastases is independently associated with a shorter overall survival.

Surprisingly, our results differed substantially from those previously reported using the scoring systems of Tokuhashi[13](#os12465-bib-0013){ref-type="ref"}, [14](#os12465-bib-0014){ref-type="ref"} and Tomita[12](#os12465-bib-0012){ref-type="ref"}. Our results were conflicting in that patients with visceral metastases did not have a significantly shorter survival time than those with spinal metastases alone. However, this finding was in accordance with other previous reports. Sellin[26](#os12465-bib-0026){ref-type="ref"} reported that visceral metastases do not affect prognosis according to multivariate analysis, their univariate analysis showed that it was significantly associated with worse overall survival. Jiang[27](#os12465-bib-0027){ref-type="ref"} identified no significant effect of the absence or presence of visceral metastases on postoperative recurrence or survival. In another study by Sciubba[28](#os12465-bib-0028){ref-type="ref"}, the median survival of patients without visceral metastases was 28.0 months, compared with 17.4 months for those with visceral metastases. However, the results of our multivariate analysis were similar to those of Arrigo[20](#os12465-bib-0020){ref-type="ref"} and Chong[21](#os12465-bib-0021){ref-type="ref"} in showing no statistically significant difference between patients with versus without visceral metastases.

In addition, visceral metastases status reportedly has a similar impact on prognosis in patients with different primary tumor types. Zadnik[29](#os12465-bib-0029){ref-type="ref"} examined the relationship of visceral metastases to survival in patients with MSCC from breast cancer and found that the median survival for those without visceral metastases was 25.9 months, compared with 28.1 months for those with visceral metastases; this difference was not significant on Mantel‐Cox testing. Chen[30](#os12465-bib-0030){ref-type="ref"} reported that visceral metastases had no statistically significant association with survival in patients with non‐small‐cell lung cancer and spinal metastases who underwent spinal surgery. The findings of Park et al. were similar[31](#os12465-bib-0031){ref-type="ref"}. In addition, Ju[32](#os12465-bib-0032){ref-type="ref"} demonstrated that visceral metastases had no statistically significant association with survival in patients with MSCC from prostate cancer and Bakker[33](#os12465-bib-0033){ref-type="ref"} found that they were not significantly associated with survival in patients with renal cell carcinoma. Walcott[34](#os12465-bib-0034){ref-type="ref"} found that the concomitant presence of visceral lesions or multi‐focal bony disease did not have prognostic significance in patients with breast cancer. Thus, the presence of progressive systemic disease should not be a contradiction to aggressive surgery, which is in agreement with previous reports by Walcott *et al.* [34](#os12465-bib-0034){ref-type="ref"}.

The explanation for our results is unclear. One possible explanation is that the presence of spinal metastases in itself denotes a more aggressive and advanced stage of cancer than the presence of visceral metastases. Thus, survival is equivalent for patients with and without visceral metastases. Another possible explanation is that advanced treatment strategies, such as targeted therapy, hormonal therapy, chemotherapy and stereotactic body radiotherapy, effectively control systemic metastases and significantly prolong the survival time of patients with MSCC. It is also possible that there was a bias in selecting patients for surgery, because patients with visceral metastasis usually have lower performance scale scores, which can be considered a contraindication for surgery. Additionally, differences in stage at diagnosis may have influenced our results. Another possibility is that visceral metastases may not affect the prognosis of certain types of primary cancer and those types may have accounted for a larger proportion of our study cohort, which may in turn have influenced our results.

*Difference in Prognosis between Patients with and without Visceral Metastases* {#os12465-sec-0016}
-------------------------------------------------------------------------------

In the current study, we did not find a correlation between the presence of visceral metastases and decreased survival. However, we found to our surprise that patients with and without visceral metastases have different prognostic factors. The factors influencing survival times of patients with visceral metastases were change on KPS and postoperative complications, whereas rate of growth of primary tumor, pre‐operative KPS, and change in KPS were significantly associated with survival in patients without visceral metastases. These findings are in agreement with previous reports that have demonstrated that KPS, neurological compromise, and primary cancer type are associated with decreased survival. However, we did no further analysis to determine why and how other prognostic factors affect survival, because we only aimed to investigate the correlation between visceral metastases and survival. Of course, we believe that identifying these prognostic differences is important for selecting optimal treatment.

*Primary Tumor* {#os12465-sec-0017}
---------------

The prognostic impact of type of primary tumor on survival of patients with MSCC has been reported previously[12](#os12465-bib-0012){ref-type="ref"}, [13](#os12465-bib-0013){ref-type="ref"}, [14](#os12465-bib-0014){ref-type="ref"}. Favorable histologic types such as breast and prostate cancer are associated with better survival prognosis than other types, whereas survival of patients with lung cancer is extraordinarily poor[20](#os12465-bib-0020){ref-type="ref"}, [35](#os12465-bib-0035){ref-type="ref"}. In our study, the rate of growth of the primary tumor was a significant prognostic factor in the whole group and the group without visceral metastases. However, we did not determine whether the type of primary tumor influences survival of patients with visceral metastases.

*KPS or Change in KPS* {#os12465-sec-0018}
----------------------

In our study, change in KPS 4 weeks postoperatively was a significant prognostic factor in the whole cohort, as well as in both groups with and without visceral metastases. Preoperative KPS was a significant prognostic factor in the whole cohort and the group without visceral metastases, but not in the group with visceral metastases. One possible explanation is that poor preoperative KPS, or no or worsening KPS, denotes a more aggressive cancer or more advanced stage. Additionally, major complications may affect the prognosis of patients with visceral metastases. However, few studies have reported the prognostic impact of complications in patients with MSCC. In our study, the findings concerning influence of complications on prognosis may be questionable because of the large difference in the number of patients with or without complications (15 vs. 154). Further study is required to better address this question.

*Limitations of the Study* {#os12465-sec-0019}
--------------------------

First, this was a retrospective review with a small number of patients with visceral metastases, the small number possibly being attributable to financial considerations and the negative attitude of Chinese people toward seeking surgical treatment, especially for patients with visceral metastases. Second, a wide variety of primary tumors were included and different tumor types may have different biological behavior and different prognoses. It would likely be useful to analyze prognosis for individual tumor types rather than grouping all tumor types together. However, Abouret *et al.* [36](#os12465-bib-0036){ref-type="ref"} reported similar results in that they found that visceral metastases were not significantly predictive of long‐term survival for various primary tumors. Third, in the present study we did not investigate the effect of chemotherapy because previous chemotherapy regimens varied between patients; those variations may have influenced survival. Last, we found it difficult to decrease heterogeneity between the two groups. Nonetheless, we believe that our findings are valid. Additionally, selection bias is inevitable in retrospective cohort studies[37](#os12465-bib-0037){ref-type="ref"}.

In summary, visceral metastases had no statistically significant association with survival in patients with MSCC; thus, more aggressive surgery should be considered for patients with visceral metastases.
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